QNRX QUOIN PHARMACEUTICALS LTD Product Launches 8-K Filing 2025 - Netherton Campaign Quoin Pharmaceuticals Ltd has launched the NETHERTON NOW campaign to raise awareness about Netherton Syndrome, a severe genetic disease, while conducting clinical studies on QRX003 as a potential treatment; as of February 4, 2025, the company has 20,585,830 outstanding ordinary shares.Get access to all SEC 8-K filings of the QUOIN PHARMACEUTICALS LTD